## Brian Nussenbaum

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5368421/publications.pdf

Version: 2024-02-01

331670 345221 1,493 39 21 36 h-index citations g-index papers 39 39 39 2200 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clinical Cancer Research, 2020, 26, 5140-5152.	7.0	163
2	Scalp Reconstruction. JAMA Facial Plastic Surgery, 2015, 17, 56-66.	2.1	143
3	Head and Neck Paragangliomas. Otolaryngology - Head and Neck Surgery, 2016, 154, 597-605.	1.9	138
4	High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer. Oral Oncology, 2015, 51, 514-520.	1.5	120
5	Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer. Cancer, 2017, 123, 4841-4850.	4.1	107
6	Multicenter Trial of [ <sup>18</sup> F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the NO Neck: Results From ACRIN 6685. Journal of Clinical Oncology, 2019, 37, 1704-1712.	1.6	80
7	Patients Undergoing Total Laryngectomy. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 1157.	2.2	59
8	<i>BRAF</i> mutation is not predictive of longâ€term outcome in papillary thyroid carcinoma. Cancer Medicine, 2015, 4, 791-799.	2.8	58
9	Comparison of unilateral versus bilateral intensityâ€modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil. Cancer, 2017, 123, 4594-4607.	4.1	46
10	Postoperative care fragmentation and thirty-day unplanned readmissions after head and neck cancer surgery. Laryngoscope, 2017, 127, 868-874.	2.0	45
11	Ex VivoGene Therapy for Skeletal Regeneration in Cranial Defects Compromised by Postoperative Radiotherapy. Human Gene Therapy, 2003, 14, 1107-1115.	2.7	43
12	Complications and 30â€day hospital readmission rates of patients undergoing tracheostomy: A prospective analysis. Laryngoscope, 2017, 127, 2746-2753.	2.0	43
13	Association of Compliance With Process-Related Quality Metrics and Improved Survival in Oral Cavity Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 430.	2.2	41
14	The role of gene therapy for craniofacial and dental tissue engineeringâ~†. Advanced Drug Delivery Reviews, 2006, 58, 577-591.	13.7	40
15	Bone Regeneration in Cranial Defects Previously Treated with Radiation. Laryngoscope, 2005, 115, 1170-1177.	2.0	36
16	Reconstruction of the Lateral Mandibular Defect. JAMA Facial Plastic Surgery, 2015, 17, 367.	2.1	33
17	30â€day hospital readmission following otolaryngology surgery: Analysis of a state inpatient database. Laryngoscope, 2017, 127, 337-345.	2.0	33
18	Evaluation of Quality Metrics for Surgically Treated Laryngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 1154.	2.2	28

#	Article	IF	CITATIONS
19	Soft tissue metastasis in p16-positive oropharynx carcinoma: Prevalence and association with distant metastasis. Oral Oncology, 2015, 51, 778-786.	1.5	27
20	High E6 Gene Expression Predicts for Distant Metastasis and Poor Survival in Patients With HPV-Positive Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1132-1141.	0.8	25
21	Tissue engineering: the current status of this futuristic modality in head neck reconstruction. Current Opinion in Otolaryngology and Head and Neck Surgery, 2004, 12, 311-315.	1.8	22
22	Definitive Surgical Therapy after Open Neck Biopsy for HPVâ€Related Oropharyngeal Cancer. Otolaryngology - Head and Neck Surgery, 2016, 154, 657-666.	1.9	19
23	Management Controversies in Head and Neck Melanoma. JAMA Facial Plastic Surgery, 2017, 19, 53-62.	2.1	19
24	Reevaluation of postoperative radiation dose in the management of human papillomavirus–positive oropharyngeal cancer. Head and Neck, 2016, 38, 1643-1649.	2.0	18
25	nab -Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. Oral Oncology, 2016, 61, 1-7.	1.5	18
26	Current State of Overlapping, Concurrent, and Multiple-Room Surgery in Otolaryngology: A National Survey. Otolaryngology - Head and Neck Surgery, 2017, 157, 998-1004.	1.9	17
27	Association of a Perioperative Education Program With Unplanned Readmission Following Total Laryngectomy. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1200.	2.2	12
28	nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. Oral Oncology, 2017, 72, 26-31.	1.5	12
29	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology, 2017, 11, 338-345.	2.6	9
30	Head & Drcology, 2017, 74, 159-162.	1.5	9
31	Full-Thickness Scalp Defects Reconstructed With Outer Table Calvarial Decortication and Surface Grafting. JAMA Facial Plastic Surgery, 2017, 19, 74-76.	2.1	7
32	National Multispecialty Survey Results: Comparing Morbidity and Mortality Conference Practices within and outside Otolaryngology. Otolaryngology - Head and Neck Surgery, 2018, 158, 273-279.	1.9	7
33	Systemic Effects of Subcutaneous Heparin Use in Otolaryngology Patients. Otolaryngology - Head and Neck Surgery, 2014, 151, 967-971.	1.9	6
34	Pre-radiotherapy feeding tube identifies a poor prognostic subset of postoperative p16 positive oropharyngeal carcinoma patients. Radiation Oncology, 2015, $10, 8$ .	2.7	6
35	Asymptomatic p16-Positive Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 975.	2.2	2
36	Looking beyond the CRT paradigm: Why induction chemotherapy is worthy of pursuit. Oral Oncology, 2015, 51, 103-104.	1.5	2

#	Article	IF	CITATIONS
37	Outcomes of P16 positive oropharyngeal squamous cell carcinoma treated with surgery and adjuvant IMRT. Journal of Radiation Oncology, 2015, 4, 37-46.	0.7	0
38	Surgical Treatment For T4 Oropharyngeal Cancerâ€"Reply. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 97.	2.2	0
39	Multidisciplinary Clinical Treatment of Head and Neck Cancerâ€"Reply. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 461.	2.2	0